Literature DB >> 31135600

Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.

Cindy L Zuleger1, Michael A Newton1,2, Xiuyu Ma2, Irene M Ong1,2,3, Qinglin Pei4, Mark R Albertini1,5,6.   

Abstract

This study examines whether 6-thioguanine resistant T cells (mutant) from metastatic melanoma patients are enriched for melanoma-associated T cells compared to T cells obtained analogously without thioguanine selection (wild-type). Melanoma-associated antigen pentamer staining was performed on 5 tumour and 9 peripheral blood samples from metastatic melanoma patients. T cell receptor beta chain repertoire was examined via Sanger sequencing of mutant and wild-type in blood and tumour from metastatic melanoma patients at times of tumour progression (n = 8) and via Illumina sequencing in tumour derived T cells and in uncultured T cells (uncultured), wild-type and mutant from blood before and after immune checkpoint blockade (n = 1). Mutant from tumour (3 of 5; P < 0.001), but not blood (0 of 9), were enriched compared to wild-type for binding melanoma-associated antigen pentamers. T cell receptor beta analysis in patients with tumour progression (n = 8) detected increased melanoma associated T cells in mutant compared to wild-type from blood (Monte Carlo P = 10). Comparison of blood samples before and after immune checkpoint blockade with prior tumor from one metastatic melanoma patient detected increased T cell receptor beta sharing between tumour and mutant compared to tumour and wild-type or tumour and uncultured: 11.0% (72/656), 1.5% (206/13 639) and 1.3% (381/29 807), respectively (Monte Carlo P = 10 for mutant versus wild-type and mutant versus uncultured). These data demonstrate that mutant in metastatic melanoma patients are enriched for melanoma-associated T cells and are candidate probes to study in vivo melanoma-reactive T cells.

Entities:  

Mesh:

Year:  2020        PMID: 31135600      PMCID: PMC6874720          DOI: 10.1097/CMR.0000000000000625

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.199


  38 in total

1.  Quantifiable predictive features define epitope-specific T cell receptor repertoires.

Authors:  Pradyot Dash; Andrew J Fiore-Gartland; Tomer Hertz; George C Wang; Shalini Sharma; Aisha Souquette; Jeremy Chase Crawford; E Bridie Clemens; Thi H O Nguyen; Katherine Kedzierska; Nicole L La Gruta; Philip Bradley; Paul G Thomas
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

2.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.

Authors:  Evan Z Macosko; Anindita Basu; Rahul Satija; James Nemesh; Karthik Shekhar; Melissa Goldman; Itay Tirosh; Allison R Bialas; Nolan Kamitaki; Emily M Martersteck; John J Trombetta; David A Weitz; Joshua R Sanes; Alex K Shalek; Aviv Regev; Steven A McCarroll
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

Review 3.  Paths to stemness: building the ultimate antitumour T cell.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

4.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Authors:  Alena Gros; Maria R Parkhurst; Eric Tran; Anna Pasetto; Paul F Robbins; Sadia Ilyas; Todd D Prickett; Jared J Gartner; Jessica S Crystal; Ilana M Roberts; Kasia Trebska-McGowan; John R Wunderlich; James C Yang; Steven A Rosenberg
Journal:  Nat Med       Date:  2016-02-22       Impact factor: 53.440

5.  Mutagenicity monitoring following battlefield exposures: Longitudinal study of HPRT mutations in Gulf War I veterans exposed to depleted uranium.

Authors:  Richard J Albertini; Pamela M Vacek; Elizabeth W Carter; Janice A Nicklas; Katherine S Squibb; Patricia W Gucer; Susan M Engelhardt; Melissa A McDiarmid
Journal:  Environ Mol Mutagen       Date:  2015-05-13       Impact factor: 3.216

6.  Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.

Authors:  Mark R Albertini; Erik A Ranheim; Cindy L Zuleger; Paul M Sondel; Jacquelyn A Hank; Alan Bridges; Michael A Newton; Thomas McFarland; Jennifer Collins; Erin Clements; Mary Beth Henry; Heather B Neuman; Sharon Weber; Giles Whalen; Uri Galili
Journal:  Cancer Immunol Immunother       Date:  2016-05-20       Impact factor: 6.968

7.  Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients.

Authors:  Mark R Albertini; Michael D Macklin; Cindy L Zuleger; Michael A Newton; Stephen A Judice; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2008-12       Impact factor: 3.216

8.  Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.

Authors:  Steven Yeh; Neel K Karne; Sid P Kerkar; Charles K Heller; Douglas C Palmer; Laura A Johnson; Zhuqing Li; Rachel J Bishop; Wai T Wong; Richard M Sherry; James C Yang; Mark E Dudley; Nicholas P Restifo; Steven A Rosenberg; Robert B Nussenblatt
Journal:  Ophthalmology       Date:  2009-05       Impact factor: 12.079

9.  UpSetR: an R package for the visualization of intersecting sets and their properties.

Authors:  Jake R Conway; Alexander Lex; Nils Gehlenborg
Journal:  Bioinformatics       Date:  2017-09-15       Impact factor: 6.937

10.  Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.

Authors:  Mariana Aris; Alicia Inés Bravo; María Betina Pampena; Paula Alejandra Blanco; Ibel Carri; Daniel Koile; Patricio Yankilevich; Estrella Mariel Levy; María Marcela Barrio; José Mordoh
Journal:  Front Immunol       Date:  2018-05-03       Impact factor: 7.561

View more
  1 in total

Review 1.  Molecular characterization of hypoxanthine guanine phosphoribosyltransferase mutant T cells in human blood: The concept of surrogate selection for immunologically relevant cells.

Authors:  Noah A Kaitz; Cindy L Zuleger; Peng Yu; Michael A Newton; Richard J Albertini; Mark R Albertini
Journal:  Mutat Res Rev Mutat Res       Date:  2022-03-11       Impact factor: 7.015

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.